世界の次世代抗体治療市場：2028年までの予測

出版：QYResearch（QYリサーチ）　出版年月：2022年9月

Global Next Generation Antibody Therapeutics Market Insights and Forecast to 2028
世界の次世代抗体治療市場インサイト：2028年までの予測

レポート目次　　お問合せ・ご注文　　価格・納期について

Market Analysis and Insights: Global Next Generation Antibody Therapeutics Market
Due to the COVID-19 pandemic and Spain-Ukraine War Influence, the global market for Next Generation Antibody Therapeutics estimated at US$ 12257.15 million in the year 2022, is projected to reach a revised size of US$ 39442.45 million by 2028, growing at a CAGR of 21.51% during the forecast period 2022-2028.
The USA market for Next Generation Antibody Therapeutics is estimated to increase from US$ 7362.24 million in 2022 to reach US$ 20256.78 million by 2028, at a CAGR of 18.38% during the forecast period of 2022-2028.
The Europe market for Next Generation Antibody Therapeutics is estimated to increase from US$ 2284.07 million in 2022 to reach US$ 9019.50 million by 2028, at a CAGR of 25.72% during the forecast period of 2022 through 2028.
The Japan market for Next Generation Antibody Therapeutics is estimated to increase from US$ 1154.2 million in 2022 to reach US$ 3337.61 million by 2028, at a CAGR of 19.36% during the forecast period of forecast years.
The global key companies of Next Generation Antibody Therapeutics include Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc. In 2021, the global top five players had a share approximately 88.78% in terms of revenue.
Report Includes
This report presents an overview of global market for Next Generation Antibody Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Next Generation Antibody Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Next Generation Antibody Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, Japan, China, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Next Generation Antibody Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Next Generation Antibody Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Next Generation Antibody Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc.

By Company
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics

Segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)

Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases

By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Next Generation Antibody Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics companies competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9: South America by Type, by Application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next Generation Antibody Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions

目次

Tables and Figures

1 Report Overview1
1.1 Study Scope1
1.2 Market Analysis by Type1
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 20281
1.2.2 Antibody Drug Conjugate (ADC)3
1.2.3 Bispecific Antibody (BsAb)3
1.3 Market by Application4
1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2017 VS 2021 VS 20285
1.3.2 Cancer6
1.3.3 Haemophilia7
1.3.4 Other Non-Cancer Diseases8
1.4 Study Objectives9
1.5 Years Considered10
2 Global Growth Trends11
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2017-2028)11
2.2 Next Generation Antibody Therapeutics Growth Trends by Region12
2.2.1 Next Generation Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 202812
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2017-2022)13
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028)14
2.3 Next Generation Antibody Therapeutics Market Dynamics15
2.3.1 Next Generation Antibody Therapeutics Industry Trends15
2.3.2 Next Generation Antibody Therapeutics Market Drivers15
2.3.3 Next Generation Antibody Therapeutics Market Challenges and Restraints16
3 Competition Landscape by Key Players17
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue17
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2017-2022)17
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2017-2022)18
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)19
3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue21
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio22
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI)22
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 202123
3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served23
3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service24
3.7 Date of Enter into Next Generation Antibody Therapeutics Market24
3.8 Mergers & Acquisitions, Expansion Plans25
4 Next Generation Antibody Therapeutics Breakdown Data by Type26
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2017-2022)26
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028)27
5 Next Generation Antibody Therapeutics Breakdown Data by Application28
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2017-2022)28
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028)29
6 North America30
6.1 North America Next Generation Antibody Therapeutics Market Size (2017-2028)30
6.2 North America Next Generation Antibody Therapeutics Market Size by Type30
6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022)30
6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028)31
6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028)31
6.3 North America Next Generation Antibody Therapeutics Market Size by Application32
6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022)32
6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028)32
6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028)33
6.4 North America Next Generation Antibody Therapeutics Market Size by Country33
6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022)33
6.4.2 North America Next Generation Antibody Therapeutics Market Share by Country (2023-2028)34
6.4.3 United States35
6.4.4 Canada35
6.4.5 Mexico36
7 Europe37
7.1 Europe Next Generation Antibody Therapeutics Market Size (2017-2028)37
7.2 Europe Next Generation Antibody Therapeutics Market Size by Type37
7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022)37
7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028)38
7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028)38
7.3 Europe Next Generation Antibody Therapeutics Market Size by Application39
7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022)39
7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028)39
7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028)40
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country40
7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022)40
7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028)41
7.4.3 Germany42
7.4.4 France42
7.4.5 U.K.43
7.4.6 Italy43
7.4.7 Spain44
8 Asia-Pacific45
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2017-2028)45
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type45
8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022)45
8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028)46
8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028)46
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application47
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022)47
8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028)47
8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028)48
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region48
8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022)48
8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028)49
8.4.3 China50
8.4.4 Japan50
8.4.5 South Korea51
8.4.6 Southeast Asia51
8.4.7 India52
9 South America53
9.1 South America Next Generation Antibody Therapeutics Market Size (2017-2028)53
9.2 South America Next Generation Antibody Therapeutics Market Size by Type53
9.2.1 South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022)53
9.2.2 South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028)54
9.2.3 South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028)54
9.3 South America Next Generation Antibody Therapeutics Market Size by Application55
9.3.1 South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022)55
9.3.2 South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028)55
9.3.3 South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028)56
9.4 South America Next Generation Antibody Therapeutics Market Size by Country56
9.4.1 South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022)56
9.4.2 South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028)57
9.4.3 Brazil58
9.4.4 Argentina58
10 Middle East & Africa59
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2017-2028)59
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type59
10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022)59
10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028)60
10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028)60
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application61
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022)61
10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028)61
10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028)62
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country62
10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022)62
10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028)63
10.4.3 Middle East64
10.4.4 Africa64
11 Key Players Profiles65
11.1 Roche65
11.1.1 Roche Company Details65
11.1.2 Roche Business Overview65
11.1.3 Roche Next Generation Antibody Therapeutics Introduction66
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022)69
11.1.5 Roche Recent Development70
11.2 Amgen70
11.2.1 Amgen Company Details70
11.2.2 Amgen Business Overview71
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction71
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022)72
11.2.5 Amgen Recent Development73
11.3 Takeda74
11.3.1 Takeda Company Details74
11.3.2 Takeda Business Overview74
11.3.3 Takeda Next Generation Antibody Therapeutics Introduction74
11.3.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022)76
11.3.5 Takeda Recent Development77
11.4 Pfizer78
11.4.1 Pfizer Company Details78
11.4.2 Pfizer Business Overview78
11.4.3 Pfizer Next Generation Antibody Therapeutics Introduction79
11.4.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022)80
11.4.5 Pfizer Recent Development81
11.5 Seagen Inc.81
11.5.1 Seagen Inc. Company Details81
11.5.2 Seagen Inc. Business Overview82
11.5.3 Seagen Inc. Next Generation Antibody Therapeutics Introduction82
11.5.4 Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022)84
11.5.5 Seagen Inc. Recent Development85
11.6 Astellas85
11.6.1 Astellas Company Details85
11.6.2 Astellas Business Overview86
11.6.3 Astellas Next Generation Antibody Therapeutics Introduction86
11.6.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022)87
11.6.5 Astellas Recent Development87
11.7 Daiichi Sankyo88
11.7.1 Daiichi Sankyo Company Details88
11.7.2 Daiichi Sankyo Business Overview88
11.7.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction89
11.7.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022)91
11.7.5 Daiichi Sankyo Recent Development91
11.8 Immunomedics (Gilead)92
11.8.1 Immunomedics (Gilead) Company Details92
11.8.2 Immunomedics (Gilead) Business Overview92
11.8.3 Immunomedics (Gilead) Next Generation Antibody Therapeutics Introduction93
11.8.4 Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022)93
11.8.5 Immunomedics (Gilead) Recent Development94
11.9 GSK94
11.9.1 GSK Company Details94
11.9.2 GSK Business Overview95
11.9.3 GSK Next Generation Antibody Therapeutics Introduction95
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022)96
11.9.5 GSK Recent Development96
11.10 Immunocore97
11.10.1 Immunocore Company Details97
11.10.2 Immunocore Business Overview97
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction98
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022)98
11.10.5 Immunocore Recent Development99
11.11 ADC Therapeutics SA99
11.11.1 ADC Therapeutics SA Company Details99
11.11.2 ADC Therapeutics SA Business Overview100
11.11.3 ADC Therapeutics SA Next Generation Antibody Therapeutics Introduction100
11.11.4 ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022)101
11.11.5 ADC Therapeutics SA Recent Development102
12 Analyst’s Viewpoints/Conclusions103
13 Appendix104
13.1 Research Methodology104
13.1.1 Methodology/Research Approach104
13.1.2 Data Source107
13.2 Disclaimer110
13.3 Author Details110

Table 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 20281
Table 2. Key Players of Antibody Drug Conjugate (ADC)3
Table 3. Key Players of Bispecific Antibody (BsAb)4
Table 4. Global Next Generation Antibody Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 20285
Table 5. Global Next Generation Antibody Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 202812
Table 6. Global Next Generation Antibody Therapeutics Market Size by Region (2017-2022) & (US$ Million)13
Table 7. Global Next Generation Antibody Therapeutics Market Share by Region (2017-2022)14
Table 8. Global Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)14
Table 9. Global Next Generation Antibody Therapeutics Market Share by Region (2023-2028)14
Table 10. Next Generation Antibody Therapeutics Market Trends15
Table 11. Next Generation Antibody Therapeutics Market Drivers15
Table 12. Next Generation Antibody Therapeutics Market Challenges and Restraints16
Table 13. Global Next Generation Antibody Therapeutics Revenue by Players (2017-2022) & (US$ Million)17
Table 14. Global Next Generation Antibody Therapeutics Market Share by Players (2017-2022)18
Table 15. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2021)20
Table 16. Ranking of Global Top Next Generation Antibody Therapeutics Companies by Revenue (US$ Million) in 202121
Table 17. Global 5 Largest Players Market Share by Next Generation Antibody Therapeutics Revenue (CR5 and HHI) & (2017-2022)22
Table 18. Key Players Headquarters and Area Served23
Table 19. Key Players Next Generation Antibody Therapeutics Product Solution and Service24
Table 20. Date of Enter into Next Generation Antibody Therapeutics Market24
Table 21. Mergers & Acquisitions, Expansion Plans25
Table 22. Global Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)26
Table 23. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2017-2022)26
Table 24. Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)27
Table 25. Global Next Generation Antibody Therapeutics Revenue Market Share by Type (2023-2028)27
Table 26. Global Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)28
Table 27. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2017-2022)28
Table 28. Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)29
Table 29. Global Next Generation Antibody Therapeutics Revenue Market Share by Application (2023-2028)29
Table 30. North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)30
Table 31. North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) & (US$ Million)31
Table 32. North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)32
Table 33. North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) & (US$ Million)32
Table 34. North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) & (US$ Million)33
Table 35. North America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) & (US$ Million)34
Table 36. Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)37
Table 37. Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028) & (US$ Million)38
Table 38. Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)39
Table 39. Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028) & (US$ Million)39
Table 40. Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022) & (US$ Million)40
Table 41. Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028) & (US$ Million)41
Table 42. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)45
Table 43. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028) & (US$ Million)46
Table 44. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)47
Table 45. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028) & (US$ Million)47
Table 46. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022) & (US$ Million)48
Table 47. Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028) & (US$ Million)49
Table 48. South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)53
Table 49. South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) & (US$ Million)54
Table 50. South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)55
Table 51. South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) & (US$ Million)55
Table 52. South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) & (US$ Million)56
Table 53. South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) & (US$ Million)57
Table 54. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022) & (US$ Million)59
Table 55. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028) & (US$ Million)60
Table 56. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022) & (US$ Million)61
Table 57. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028) & (US$ Million)61
Table 58. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022) & (US$ Million)62
Table 59. Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028) & (US$ Million)63
Table 60. Roche Company Details65
Table 61. Roche Business Overview65
Table 62. Roche Next Generation Antibody Therapeutics Product66
Table 63. Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)69
Table 64. Roche Recent Development70
Table 65. Amgen Company Details70
Table 66. Amgen Business Overview71
Table 67. Amgen Next Generation Antibody Therapeutics Product71
Table 68. Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)72
Table 69. Amgen Recent Development73
Table 70. Takeda Company Details74
Table 71. Takeda Business Overview74
Table 72. Takeda Next Generation Antibody Therapeutics Product74
Table 73. Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)76
Table 74. Takeda Recent Development77
Table 75. Pfizer Company Details78
Table 76. Pfizer Business Overview78
Table 77. Pfizer Next Generation Antibody Therapeutics Product79
Table 78. Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)80
Table 79. Pfizer Recent Development81
Table 80. Seagen Inc. Company Details81
Table 81. Seagen Inc. Business Overview82
Table 82. Seagen Inc. Next Generation Antibody Therapeutics Product82
Table 83. Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)84
Table 84. Seagen Inc. Recent Development85
Table 85. Astellas Company Details85
Table 86. Astellas Business Overview86
Table 87. Astellas Next Generation Antibody Therapeutics Product86
Table 88. Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)87
Table 89. Astellas Recent Development87
Table 90. Daiichi Sankyo Company Details88
Table 91. Daiichi Sankyo Business Overview88
Table 92. Daiichi Sankyo Next Generation Antibody Therapeutics Product89
Table 93. Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)91
Table 94. Daiichi Sankyo Recent Development91
Table 95. Immunomedics (Gilead) Company Details92
Table 96. Immunomedics (Gilead) Business Overview92
Table 97. Immunomedics (Gilead) Next Generation Antibody Therapeutics Product93
Table 98. Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)93
Table 99. Immunomedics (Gilead) Recent Development94
Table 100. GSK Company Details94
Table 101. GSK Business Overview95
Table 102. GSK Next Generation Antibody Therapeutics Product95
Table 103. GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)96
Table 104. GSK Recent Development96
Table 105. Immunocore Company Details97
Table 106. Immunocore Business Overview97
Table 107. Immunocore Next Generation Antibody Therapeutics Product98
Table 108. Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)98
Table 109. Immunocore Recent Development99
Table 110. ADC Therapeutics SA Company Details99
Table 111. ADC Therapeutics SA Business Overview100
Table 112. ADC Therapeutics SA Next Generation Antibody Therapeutics Product100
Table 113. ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022) & (US$ Million)101
Table 114. ADC Therapeutics SA Recent Development102
Table 115. Research Programs/Design for This Report104
Table 116. Key Data Information from Secondary Sources107
Table 117. Key Data Information from Primary Sources109

List of Figures

Figure 1. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)2
Figure 2. Global Next Generation Antibody Therapeutics Market Share by Type: 2021 VS 20282
Figure 3. Antibody Drug Conjugate (ADC) Features3
Figure 4. Bispecific Antibody (BsAb) Features4
Figure 5. Global Next Generation Antibody Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)5
Figure 6. Global Next Generation Antibody Therapeutics Market Share by Application: 2021 VS 20286
Figure 7. Global Next Generation Antibody Therapeutics Market Size in Case of Cancer Applications7
Figure 8. Global Next Generation Antibody Therapeutics Market Size in Case of Haemophilia Applications8
Figure 9. Global Next Generation Antibody Therapeutics Market Size in Case of Other Non-Cancer Diseases9
Figure 10. Next Generation Antibody Therapeutics Report Years Considered10
Figure 11. Global Next Generation Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2017-202811
Figure 12. Global Next Generation Antibody Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 202812
Figure 13. Global Next Generation Antibody Therapeutics Market Share by Region: 2021 VS 202813
Figure 14. Global Next Generation Antibody Therapeutics Market Share by Players in 202119
Figure 15. Global Top Next Generation Antibody Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Antibody Therapeutics as of 2021)20
Figure 16. The Top 10 and 5 Players Market Share by Next Generation Antibody Therapeutics Revenue in 202123
Figure 17. North America Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)30
Figure 18. North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028)31
Figure 19. North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028)33
Figure 20. North America Next Generation Antibody Therapeutics Market Share by Country (2017-2028)34
Figure 21. United States Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)35
Figure 22. Canada Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)35
Figure 23. Mexico Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)36
Figure 24. Europe Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)37
Figure 25. Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028)38
Figure 26. Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028)40
Figure 27. Europe Next Generation Antibody Therapeutics Market Share by Country (2017-2028)41
Figure 28. Germany Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)42
Figure 29. France Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)42
Figure 30. U.K. Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)43
Figure 31. Italy Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)43
Figure 32. Spain Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)44
Figure 33. Asia-Pacific Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)45
Figure 34. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028)46
Figure 35. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028)48
Figure 36. Asia-Pacific Next Generation Antibody Therapeutics Market Share by Region (2017-2028)49
Figure 37. China Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)50
Figure 38. Japan Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)50
Figure 39. South Korea Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)51
Figure 40. Southeast Asia Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)51
Figure 41. India Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)52
Figure 42. South America Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)53
Figure 43. South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028)54
Figure 44. South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028)56
Figure 45. South America Next Generation Antibody Therapeutics Market Share by Country (2017-2028)57
Figure 46. Brazil Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)58
Figure 47. Argentina Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)58
Figure 48. Middle East & Africa Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)59
Figure 49. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028)60
Figure 50. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028)62
Figure 51. Middle East & Africa Next Generation Antibody Therapeutics Market Share by Country (2017-2028)63
Figure 52. Middle East Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)64
Figure 53. Africa Next Generation Antibody Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)64
Figure 54. Roche Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)69
Figure 55. Amgen Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)73
Figure 56. Takeda Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)77
Figure 57. Pfizer Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)81
Figure 58. Seagen Inc. Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)85
Figure 59. Astellas Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)87
Figure 60. Daiichi Sankyo Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)91
Figure 61. Immunomedics (Gilead) Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)94
Figure 62. GSK Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)96
Figure 63. Immunocore Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)99
Figure 64. ADC Therapeutics SA Revenue Growth Rate in Next Generation Antibody Therapeutics Business (2017-2022)102
Figure 65. Bottom-up and Top-down Approaches for This Report106
Figure 66. Data Triangulation107
Figure 67. Key Executives Interviewed109